Clinical Trial Update: Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing GSK HPV vaccine immunogenicity to Merck's Gardasil in healthy women 18-45, with completed status and results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Papillomavirus Vaccine-related Conditions

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• GlaxoSmithKline HPV vaccine (580299) (HPV vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus, Papillomavirus Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2010-08-25